Company Resverlogix Corp.

Stocks

RVX

CA76128M1086

Biotechnology & Medical Research

Delayed Toronto S.E. 21:15:49 06/11/2026 +04			5-day change	1st Jan Change
0.0800 ^CAD	+14.29%		+6.67%	-20.00%

09-10	Resverlogix Announces Publication Of Scientific Journal Articles Relating To Apabetalone's Prevention Of Heart Failure	CI
08-14	Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Business description: Resverlogix Corp.

Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Sales by Activity: Resverlogix Corp.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all business segments

Geographical breakdown of sales: Resverlogix Corp.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all geographic segments

Executive Committee: Resverlogix Corp.

Manager	Title	Age	Since
Donald McCaffrey CEO	Chief Executive Officer	-	25/04/2003
Anthony Cann DFI	Director of Finance/CFO	78	29/10/2009
Ewelina Kulikowski CTO	Chief Tech/Sci/R&D Officer	-	15/08/2022
Michael Sweeney CTO	Chief Tech/Sci/R&D Officer	65	03/11/2014

See RESVERLOGIX CORP. governance

Composition of the Board of Directors: Resverlogix Corp.

Director	Title	Age	Since
Kenneth Zuerblis BRD	Director/Board Member	66	29/09/2010
Donald McCaffrey CHM	Chairman	-	04/04/2016
Kelly McNeill BRD	Director/Board Member	56	15/10/2009
Siu Lun To BRD	Director/Board Member	57	19/12/2019
Bradley J Glass BRD	Director/Board Member	-	18/11/2025

Composition of the Board of Directors

Shareholders: Resverlogix Corp.

Name	Stocks	%	Valuation
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 24.77 %	85,286,524	24.77 %	6 M $
Donald McCaffrey 1.529 %	5,263,266	1.529 %	357 902 $
Anthony Cann 0.6048 %	2,082,255	0.6048 %	141 593 $
Kenneth Zuerblis 0.0311 %	107,062	0.0311 %	7 280 $
Kelly McNeill 0.0305 %	105,000	0.0305 %	7 140 $

List of RESVERLOGIX CORP. shareholders

Company details: Resverlogix Corp.

Resverlogix Corp.

4820 Richard Road SW

T3E 6L1, Calgary

+403 254 9252

http://www.resverlogix.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RESVERLOGIX CORP.	+14.29%	+6.67%	-15.79%	+14.29%	17.22M
WUXI APPTEC CO., LTD.	-4.83%	+2.88%	+55.87%	+69.12%	69.4B
ARGENX SE	+0.02%	+1.07%	+10.63%	+76.66%	57.24B
LONZA GROUP AG	-1.34%	+2.98%	+24.79%	+100.18%	57.62B
IQVIA HOLDINGS INC.	+2.57%	+1.65%	+28.88%	+36.97%	43.65B
BEONE MEDICINES AG	+5.78%	+10.57%	+23.20%	+108.77%	44.03B
REVOLUTION MEDICINES, INC.	+8.40%	+0.94%	+214.61%	+796.49%	38.08B
CELLTRION, INC.	-1.86%	+11.46%	+26.67%	+61.40%	36.31B
GENMAB A/S	-2.97%	-9.84%	+88.86%	+76.17%	32.61B
WUXI BIOLOGICS (CAYMAN) INC.	-2.18%	+5.68%	+36.21%	-0.69%	25.47B
Average	+1.80%	+0.76%	+49.39%	+133.94%	40.44B
Weighted average by Cap.	+0.16%	+2.44%	+52.31%	+139.42%